BioSpace News Archive

Over the weekend at its quarterly meeting, the national board of directors for the American Liver Foundation announced the election of a new board chair, Emmanuel Thomas, MD, PhD, FAASLD, Associate Professor, Pathology and Laboratory Medicine at the University of Miami Miller School of Medicine.

Olympus announced it is hosting a webinar led by interventional pulmonologist George Cheng, MD, PhD, from UC San Diego Health, who will review the full results from his study comparing the performance of reusable bronchoscopes to that of single-use bronchoscopes.

Researchers from Children’s Hospital of Philadelphia have found that adolescents who report strong relationships with their parents have better long-term health outcomes.

Aviv Clinics is sharing the results of a new study that shows hyperbaric oxygen therapy is more effective than pharmaceutical treatment in fibromyalgia patients following traumatic brain injury.

GTC—NVIDIA today announced that it is collaborating with Medtronic, the world’s largest healthcare technology provider, to accelerate the development of AI in the healthcare system and bring new AI-based solutions into patient care.

Psycheceutical Bioscience, Inc. (“Psycheceutical” or the “Company”) (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced the publication of pre-clinical observational data that supports the potential of its NeuroDirect™ ketamine topical cream as a treatment for PTSD.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) and Quantum Leap Healthcare Collaborative™ today announce that Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, will be evaluated in a new study arm of the ongoing I-SPY 2 clinical trial.

Integrated BioPharma, Inc. announced that Edward G. Kay, the Company’s Founder, Executive Chairman and President passed away yesterday evening.

Carbios (Euronext Growth Paris: ALCRB) (Paris:ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastics and textiles, announces the publication of an article entitled “Enzymes’ power for plastics degradation” in Chemical Reviews, one of the 10 most influential scientific journals in the world.

Surgalign Holdings, Inc. today announced its plans to release financial results for its fourth quarter and full year 2022 after the close of trading on March 30, 2023.